IOM Proposals for Overhaul at CIRM Win High Marks
By David Jensen,
California Stem Cell Report
| 12. 07. 2012
[Quotes CGS's Marcy Darnovsky]
The Institute of Medicine's recommendations for major changes at the California stem cell agency today received generally high marks from independent observers and critics.
Many of the proposals echoed suggestions from California's Little Hoover Commission, the state's good government agency. Asked for comment, Stuart Drown, the commission's executive director, said,
“The institute’s recommendations for much-needed changes to CIRM’s governance structure to provide greater efficiency, clarity and accountability reinforce the recommendations the Little Hoover Commission made in 2009."
He continued,
“Then and now, the Commission’s recommendations are aimed at improving
CIRM’s ability to meet its goals for the good of all who can benefit
from stem cell research, and to ensure that California taxpayers’
dollars are put to their most efficient use to that end.”
The California Stem Cell Report also asked the agency's first president,
Zach Hall, for his thoughts. Here is the full text of what Hall, who
was one of the peer reviewers on the IOM study, had to say,
“The IOM Committee and its staff have done an impressive job. The
report recognizes the scientific value and...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...